论文部分内容阅读
目的探讨血脂康对急性冠脉综合征(ACS)患者血浆白细胞介素-6(IL-6)及单核细胞趋化因子-1(MCP-1)的影响。方法采用酶联免疫吸附实验(ELISA)检测80例ACS患者服用血脂康前后血浆IL-6及MCP-1水平。结果 ACS组血浆IL-6、MCP-1水平为(25.45±6.34)ng/mL、(19.98±4.57)pg/L,显著高于对照组的(19.68±5.54)ng/mL和(14.45±4.35)pg/L(P<0.01),服用血脂康4周后血浆IL-6及MCP-1水平下降(P<0.01)。结论 ACS患者血浆IL-6及MCP-1水平升高与冠脉炎症反应相关,血脂康可显著降低ACS患者血浆IL-6及MCP-1水平,改善冠心病患者的预后。
Objective To investigate the effects of Xuezhikang on plasma interleukin-6 (IL-6) and monocyte chemotactic factor-1 (MCP-1) in patients with acute coronary syndrome (ACS). Methods Serum levels of IL-6 and MCP-1 in 80 patients with ACS were measured by enzyme linked immunosorbent assay (ELISA). Results The levels of plasma IL-6 and MCP-1 in ACS group were (25.45 ± 6.34) ng / mL and (19.98 ± 4.57) pg / L, significantly higher than those in control group (19.68 ± 5.54 ng / mL and 14.45 ± 4.35 ) pg / L (P <0.01). After taking Xuezhikang for 4 weeks, the levels of plasma IL-6 and MCP-1 decreased (P <0.01). Conclusion Serum levels of IL-6 and MCP-1 in patients with ACS are associated with coronary inflammation. Xuezhikang can significantly decrease the plasma levels of IL-6 and MCP-1 and improve the prognosis of patients with coronary heart disease.